Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  MedicationPractice MgmtIssue 666

Good or Bad News for Medicare Diabetes Patients?

Medicare and Medicaid competitive bidding may result in limited options….

Advertisement

After successfully piloting the first round in nine regions, the Centers for Medicare and Medicaid Services (CMS) will expand the competitive bidding program for durable medical equipment (DME) and mail-order programs across the nation starting in July. In the first round, the program brought down the cost for certain supplies an average of 45 percent for Medicare patients.

The cost of diabetes supplies such as blood glucose meter, test strips, and lancets are expected to be reduced an average of 72 percent through a national mail-order program. According to CMS, "The Medicare program will save $25.7 billion and beneficiaries will save $17.1 billion between 2013 and 2022."

However, not everyone is happy with the new program. The DME industry, including manufacturers, suppliers and providers of medical equipment, believe that the new program "is offering fewer and lowest-cost products" which will substantially discourage providers from offering brand name or more advanced products.

The agency has used real-time monitoring data that showed very few beneficiary complaints and no negative impact on beneficiary health status compared with non-competitive bidding areas. The program will continue to expand under close monitoring.

“We will continue to monitor the program closely as it expands to ensure the same success we saw in the program last year, with beneficiaries continuing to have access to all the services they need, while paying a much lower price,” said Jonathan Blum, deputy CMS administrator and director of CMS’ Center for Medicare.

CMS Feb 21, 2013 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 28 February, 2013 and appeared in  MedicationPractice MgmtIssue 666

Past five issues: Issue 796 | Diabetes Clinical Mastery Series Issue 255 | Issue 795 | SGLT-2 Inhibitors Special Edition August 2015 | Diabetes Clinical Mastery Series Issue 254 |

2015 Most Popular Articles:

Coffee Consumption Proves Potential in Reducing Type 2 Diabetes Risk
Posted August 07, 2015
Impaired Glucose Uptake in the Brain May Increase Alzheimer's Disease Risk
Posted August 07, 2015
Ketoacidosis Not as Great as Thought in Diabetes Patients Taking Invokana
Posted August 13, 2015
First Non-Surgical Weight Loss Procedure for Mild-to-Moderate Obesity
Posted August 07, 2015
Impact of Switching Insulin Glargine to Insulin Detemir in T2 Patients
Posted August 14, 2015
SIgnificant Weight Gain Associated with Laparoscopic Sleeve Gastrectomy
Posted August 14, 2015
GLP-1 Agonist Semaglutide Completes Phase III Trial with Positive Results
Posted August 07, 2015
Diabetes Combination Drug LixiLan Meets Main Target in Late Stage Trial
Posted August 07, 2015
Two New Possible Methods for Diagnosing and Monitoring Diabetes
Posted August 07, 2015
Soybean Oil Causes More Obesity and Diabetes Than Fructose
Posted August 20, 2015


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
What percentage of your patients have reached goal for A1c, BP and cholesterol?

CME/CE of the Week
Aaron Vinik, MD

Category: General Diabetes
Credits: 1.25